Pembrolizumab-associated anti-MDA5 dermatomyositis in a patient with lung cancer: a first case report
We report the first case of anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis as a systemic immune-related adverse event in a 64-year-old man receiving pembrolizumab to treat advanced lung cancer. The patient experienced hypothyroidism, myalgia, skin involvement, dyspnoea and diarrhoea. Laboratory tests revealed raised inflammatory markers, hypercreatinekinasemia and anti-MDA5 autoantibodies. Electroneuromyography and pathognomonic signs on physical examination confirmed the diagnosis of pauci-myopathic dermatomyositis. Pembrolizumab was discontinued and immunosuppressive therapy led to rapid and progressive improvement, with complete remission of dermatomyositis. This case report widens the spectrum of systemic immune-related adverse events associated with pembrolizumab.PMID:38579289 | DOI:10.57187/s.3513
Source: Swiss Medical Weekly - Category: General Medicine Authors: Antonino Marcello Pilia Lorenzo Salvati Alessia Guidolin Francesca Mazzoni Lorenzo Antonuzzo Paola Parronchi Francesco Liotta Source Type: research
More News: Cancer | Cancer & Oncology | Dermatology | Dermatomyositis | Diarrhoea | General Medicine | Genetics | Hypothyroidism | Laboratory Medicine | Lung Cancer | Melanoma | Skin | Skin Cancer | Switzerland Health